BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 19918062)

  • 21. Comparison of Heterologous Prime-Boost Strategies against Human Immunodeficiency Virus Type 1 Gag Using Negative Stranded RNA Viruses.
    Lawrence TM; Wanjalla CN; Gomme EA; Wirblich C; Gatt A; Carnero E; García-Sastre A; Lyles DS; McGettigan JP; Schnell MJ
    PLoS One; 2013; 8(6):e67123. PubMed ID: 23840600
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elicitation of both anti HIV-1 Env humoral and cellular immunities by replicating vaccinia prime Sendai virus boost regimen and boosting by CD40Lm.
    Zhang X; Sobue T; Isshiki M; Makino S; Inoue M; Kato K; Shioda T; Ohashi T; Sato H; Komano J; Hanabusa H; Shida H
    PLoS One; 2012; 7(12):e51633. PubMed ID: 23236521
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel vaccination protocol with two live mucosal vectors elicits strong cell-mediated immunity in the vagina and protects against vaginal virus challenge.
    Li Z; Zhang M; Zhou C; Zhao X; Iijima N; Frankel FR
    J Immunol; 2008 Feb; 180(4):2504-13. PubMed ID: 18250460
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HIV-1 Subtype C Mosaic Gag Expressed by BCG and MVA Elicits Persistent Effector T Cell Responses in a Prime-Boost Regimen in Mice.
    Jongwe TI; Chapman R; Douglass N; Chetty S; Chege G; Williamson AL
    PLoS One; 2016; 11(7):e0159141. PubMed ID: 27427967
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens.
    Asbach B; Kliche A; Köstler J; Perdiguero B; Esteban M; Jacobs BL; Montefiori DC; LaBranche CC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Landucci G; Forthal DN; Seaman MS; Hawkins N; Self SG; Sato A; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Francis J; Galmin L; Ding S; Heeney JL; Pantaleo G; Wagner R
    J Virol; 2016 Apr; 90(8):4133-4149. PubMed ID: 26865719
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Newcastle disease virus expressing a dendritic cell-targeted HIV gag protein induces a potent gag-specific immune response in mice.
    Maamary J; Array F; Gao Q; García-Sastre A; Steinman RM; Palese P; Nchinda G
    J Virol; 2011 Mar; 85(5):2235-46. PubMed ID: 21159873
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prime-boost vaccination with HIV-1 Gag protein and cytosine phosphate guanosine oligodeoxynucleotide, followed by adenovirus, induces sustained and robust humoral and cellular immune responses.
    Tritel M; Stoddard AM; Flynn BJ; Darrah PA; Wu CY; Wille U; Shah JA; Huang Y; Xu L; Betts MR; Nabel GJ; Seder RA
    J Immunol; 2003 Sep; 171(5):2538-47. PubMed ID: 12928404
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Priming with recombinant auxotrophic BCG expressing HIV-1 Gag, RT and Gp120 and boosting with recombinant MVA induces a robust T cell response in mice.
    Chapman R; Stutz H; Jacobs W; Shephard E; Williamson AL
    PLoS One; 2013; 8(8):e71601. PubMed ID: 23977084
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo electroporation in DNA-VLP prime-boost preferentially enhances HIV-1 envelope-specific IgG2a, neutralizing antibody and CD8 T cell responses.
    Huang X; Zhu Q; Huang X; Yang L; Song Y; Zhu P; Zhou P
    Vaccine; 2017 Apr; 35(16):2042-2051. PubMed ID: 28318765
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heterologous prime-boost regimens using rAd35 and rMVA vectors elicit stronger cellular immune responses to HIV proteins than homologous regimens.
    Ratto-Kim S; Currier JR; Cox JH; Excler JL; Valencia-Micolta A; Thelian D; Lo V; Sayeed E; Polonis VR; Earl PL; Moss B; Robb ML; Michael NL; Kim JH; Marovich MA
    PLoS One; 2012; 7(9):e45840. PubMed ID: 23049876
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dendritic cell targeted HIV-1 gag protein vaccine provides help to a recombinant Newcastle disease virus vectored vaccine including mobilization of protective CD8
    Ngu LN; Nji NN; Ambada G; Ngoh AA; Njambe Priso GD; Tchadji JC; Lissom A; Magagoum SH; Sake CN; Tchouangueu TF; Chukwuma GO; Okoli AS; Sagnia B; Chukwuanukwu R; Tebit DM; Esimone CO; Waffo AB; Park CG; Überla K; Nchinda GW
    Immun Inflamm Dis; 2018 Mar; 6(1):163-175. PubMed ID: 29205929
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral vaccination with a recombinant Salmonella vaccine vector provokes systemic HIV-1 subtype C Gag-specific CD4+ Th1 and Th2 cell immune responses in mice.
    Chin'ombe N; Bourn WR; Williamson AL; Shephard EG
    Virol J; 2009 Jun; 6():87. PubMed ID: 19555490
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8
    Li SS; Kochar NK; Elizaga M; Hay CM; Wilson GJ; Cohen KW; De Rosa SC; Xu R; Ota-Setlik A; Morris D; Finak G; Allen M; Tieu HV; Frank I; Sobieszczyk ME; Hannaman D; Gottardo R; Gilbert PB; Tomaras GD; Corey L; Clarke DK; Egan MA; Eldridge JH; McElrath MJ; Frahm N;
    Clin Vaccine Immunol; 2017 Nov; 24(11):. PubMed ID: 28931520
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Heterologous HIV-based lentiviral/adenoviral vectors immunizations result in enhanced HIV-specific immunity.
    Asefa B; Korokhov N; Lemiale F
    Vaccine; 2010 Apr; 28(20):3617-24. PubMed ID: 20051277
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses.
    García-Arriaza J; Nájera JL; Gómez CE; Tewabe N; Sorzano CO; Calandra T; Roger T; Esteban M
    PLoS One; 2011; 6(8):e24244. PubMed ID: 21909386
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased T cell breadth and antibody response elicited in prime-boost regimen by viral vector encoded homologous SIV Gag/Env in outbred CD1 mice.
    Andersson AC; Holst PJ
    J Transl Med; 2016 Dec; 14(1):343. PubMed ID: 27998269
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel candidate HIV vaccine vector based on the replication deficient Capripoxvirus, Lumpy skin disease virus (LSDV).
    Shen YJ; Shephard E; Douglass N; Johnston N; Adams C; Williamson C; Williamson AL
    Virol J; 2011 May; 8():265. PubMed ID: 21624130
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction of HIV-specific T and B cell responses with a replicating and conditionally infectious lentiviral vaccine.
    Wingard JB; Anderson B; Weissman D
    Eur J Immunol; 2008 May; 38(5):1310-20. PubMed ID: 18412164
    [TBL] [Abstract][Full Text] [Related]  

  • 39. mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients.
    Van Gulck E; Vlieghe E; Vekemans M; Van Tendeloo VF; Van De Velde A; Smits E; Anguille S; Cools N; Goossens H; Mertens L; De Haes W; Wong J; Florence E; Vanham G; Berneman ZN
    AIDS; 2012 Feb; 26(4):F1-12. PubMed ID: 22156965
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of a self-inactivating lentiviral vector expressing simian immunodeficiency virus gag for induction of specific immune responses in vitro and in vivo.
    Buffa V; Negri DR; Leone P; Borghi M; Bona R; Michelini Z; Compagnoni D; Sgadari C; Ensoli B; Cara A
    Viral Immunol; 2006; 19(4):690-701. PubMed ID: 17201664
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.